Cogent Biosciences, Inc. Common Stock COGT
i
Market datapartial · fetched 2026-11-11T05:54:50.694Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T22:58:13.980589851Z
FundamentalsAlpha Vantage · unavailable
Cogent Biosciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 27.39 | 124.1% | 16.0% | |||
| 25Δ | 28.23 | 127.0% | 14.4% | |||
| 30Δ | 29.01 | 136.6% | 13.1% | |||
| 35Δ | 29.86 | 140.8% | 11.7% | |||
| 40Δ | 33.23 | 89.9% | 8.6% | |||
| 45Δ | 32.57 | 83.4% | 6.9% | 31.62 | 127.0% | 8.0% |
| 50Δ | 32.32 | 127.6% | 7.1% | |||
| 55Δ | 32.92 | 111.4% | 5.3% | |||
| 60Δ | 30.78 | 135.7% | 7.1% | |||
| 65Δ | 30.04 | 120.5% | 5.1% | |||
| 70Δ | 29.21 | 122.5% | 4.2% | |||
| 75Δ | 28.16 | 132.8% | 3.5% | |||
| 80Δ | 26.85 | 146.2% | 2.9% | 37.46 | 113.0% | 1.8% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 27.39
- IV
- 124.1%
- B/E move
- 16.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 28.23
- IV
- 127.0%
- B/E move
- 14.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 29.01
- IV
- 136.6%
- B/E move
- 13.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 29.86
- IV
- 140.8%
- B/E move
- 11.7%
40Δ
- Pseudo strike
- 33.23
- IV
- 89.9%
- B/E move
- 8.6%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 32.57
- IV
- 83.4%
- B/E move
- 6.9%
- Pseudo strike
- 31.62
- IV
- 127.0%
- B/E move
- 8.0%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 32.32
- IV
- 127.6%
- B/E move
- 7.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 32.92
- IV
- 111.4%
- B/E move
- 5.3%
60Δ
- Pseudo strike
- 30.78
- IV
- 135.7%
- B/E move
- 7.1%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 30.04
- IV
- 120.5%
- B/E move
- 5.1%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 29.21
- IV
- 122.5%
- B/E move
- 4.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 28.16
- IV
- 132.8%
- B/E move
- 3.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 26.85
- IV
- 146.2%
- B/E move
- 2.9%
- Pseudo strike
- 37.46
- IV
- 113.0%
- B/E move
- 1.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 68.01% | |
| 67.68% | |
| 68.06% | |
| 67.43% | |
| 70.77% | |
| 70.79% | |
| 68.67% | |
| 68.34% | |
| 67.78% | |
| 74.14% |
Biotechnology
CORT
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company…
More →COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is…
More →CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid…
More →CRBU
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies…
More →CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
More →CRMD
Description unavailable
More →